Hengrui Pharma reports 88.9% rise in 2026 third-quarter profit on licensing deals

What happened

Hengrui Pharma reported an 88.9% rise in third-quarter 2026 profit to 2.5 billion yuan ($375 million), up from 1.3 billion a year earlier, driven by income from out-licensing deals. Operating revenue rose 21% to 9 billion yuan.

Confirmed

Global impact / market context

Licensing deals bring in cash without relying on drug sales, which matters because Beijing's centralised bulk buying programmes squeeze revenue from older medicines. Higher profit gives Hengrui more money to fund research and reduce dependence on price-pressured generics.

Analyst inference

Hengrui shares are down about 23% this year, worse than a 2% fall in the Hang Seng Biotech Index, so results beat one analyst's forecast but investor positioning stays cautious. Global drugmakers seeking China-developed medicines support deal income.

Analyst inference

What to watch

1. Hengrui completed 13 overseas business development deals since 2023, and in September said Novo Nordisk would pay up to $2.6 billion for rights to an experimental weight-loss pill. Confirmed
2. Watch whether new licensing agreements keep adding to profit, since deal income can be uneven between quarters and may not repeat at the same pace. Proposed
3. Track progress of Hengrui's 10 innovative medicines in Phase I clinical development by end of first-half 2026, because later-stage success supports future licensing revenue. Analyst inference

Evidence

• Original source link unavailable